AIM
TEVA icon

Artemis Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Artemis Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-473,564
Closed -$10.4M – 233
2024
Q4 		$10.4M Sell
473,564
-69,340
-13% -$1.26M 0.15% 137
2024
Q3 		$9.78M Buy
+542,904
New +$9.5M 0.15% 137
2020
Q3 		– Sell
-50,000
Closed -$618K – 277
2020
Q2 		$618K Buy
+50,000
New +$565K 0.01% 241
2015
Q2 		– Sell
-165,794
Closed -$10.3M – 282
2015
Q1 		$10.3M Buy
165,794
+104,394
+170% +$6.07M 0.41% 56
2014
Q4 		$3.53M Buy
+61,400
New +$3.42M 0.14% 144

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Artemis Investment Management's TEVA Position: Q1 2025 in Review

Artemis Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 473,564 shares — an estimated $10.4M sold.

Artemis Investment Management first reported a position in TEVA in Q4 2014 and held it in 5 quarters. The position peaked at $10.4M in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Artemis Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Artemis Investment Management sold 473,564 Teva Pharmaceuticals shares in Q1 2025, an estimated $10.4M.
  • Artemis Investment Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Artemis Investment Management's Teva Pharmaceuticals position peaked at $10.4M in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Artemis Investment Management's 13F filing for Q1 2025, filed 24 Apr 2025.